Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference

Portland, Oregon, June 8, 2023 — Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference. The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.

• Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?

• Presenters: Frank S. Czerwiec, MD, PhD, Chief Medical Officer at Sparrow Pharmaceuticals; David A. Katz, PhD, Chief Scientific Officer, Sparrow Pharmaceuticals; Paul M. Stewart, MD, FRCP, FMedSci, University of Leeds, UK

• Presentation number: SAT-281

• Session Category: P71 - Clinical Adrenal & Pituitary: Adrenal Basic Science/Animal Models

• Date: Saturday, June 17, 2023 at 1:00pm-2:00pm CT

SPI-62 is a potent HSD-1 inhibitor in clinical development for treatment of Cushing’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In prior Phase 1 and Phase 2 clinical trials, SPI-62 was associated with maximal liver, adipose, and brain HSD-1 inhibition at generally well tolerated doses.